Oral anticoagulation for nonvalvular atrial fibrillation: Are scientific recommendations effective and safe in daily clinical practice?;Anticoagulación oral en la fibrilación auricular no valvular: ¿son efectivas y seguras las recomendaciones científicas en la práctica clínica diaria?

Revista Espanola de Cardiologia

Volumn 59, Issue 7, 2006, Pages 688-695

  Ruiz Ortiz, Martín ^a,b   Romo Peñas, Elias ^a   Franco Zapata, Manuel ^a   Mesa Rubio, Dolores ^a   Anguita Sánchez, Manuel ^a   Delgado Ortega, Mónica ^a   Castillo Domínguez, Juan C ^a   López Granados, Amador ^a   Arizon del Prado, José M ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b NONE   (Spain)

Author keywords

Anticoagulants; Atrial fibrillation; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; OUTPATIENT; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; THROMBOEMBOLISM; TIME SERIES ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 33748473159     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13091370     Document Type: Article

References (25)

1. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Prystowsky EN, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2001;22: 1852-923.
2. Heras M, Fernández A, Gómez JA, Iriarte JA, Lidón RM. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Rev Esp Cardiol. 1999;52:801-20.
3. Almendral J, Marín E, Medina O, Peinado R, Pérez L, Ruiz R, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. Rev Esp Cardiol. 2001;54:307-67.
4. Vázquez Ruiz de Castroviejo E, Martín Rubio A, Pousibet Sanfeliu H, Lozano Cabezas C, Guzmán Herrera M, Tarabini Castellani A, et al. Utilización del tratamiento anticoagulante en los pacientes con fibrilación auricular no reumática. Rev Esp Cardiol. 2000;53:200-4.
5. Filippi A, Bettoncelli G, Zaninelli. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract. 2000;17:337-9.
6. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31: 1217-22.
7. Leckey RG, Aguilar E, Phillips SJ. Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol. 2000;16:481-5.
8. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-34.
9. Mead GE, Wardlaw JM, Lewis SC, McDowall M, Dennis MS. The influence of randomized trials on the use of anticoagulants for atrial fibrillation. Age Ageing. 1999;28:441-6.
10. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, et al. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart. 1999;82:563-9.
11. Blanch P, Freixa R, Ibernón M, Delso J, Salas E, Sobrepera JL, et al. Utilización de anticoagulantes orales en pacientes con fibrilación auricular al alta hospitalaria en el año 2000. Rev Esp Cardiol. 2003;56:1057-63.
12. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164:55-60.
13. Aronow WS, Ahn C, Kronzon I, Gutstein H. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000; 85:1033-5.
14. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-92.
15. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther. 2004;26:1470-8.
16. Frost L, Johnsen SP, Pedersen L, Toft E, Husted S, Sorensen HT. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med. 2002;252:64-9.
17. Ruiz Ortiz M, Romo Penas E, Franco Zapata MF, Mesa Rubio D, Anguita Sánchez M, López Granados A, et al. Un protocolo prospectivo permite incrementar la utilización de anticoagulación oral en pacientes con fibrilación auricular crónica no valvular. Rev Esp Cardiol. 2003;56:971-7.
18. Ruiz Ortiz M, Romo Peñas E, Franco Zapata MF, Mesa Rubio D, Anguita Sanchez M, López Granados A, et al. Oral anticoagulation in patients aged 75 years or older with chronic non-valvar atrial fibrillation: effectiveness and safety in daily clinical practice. Heart. 2005;91:1225-6.
19. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999; 131:688-95.
20. Atrial Fibrillation Investigators. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation, analysis of pooled later from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
21. Freixa R, Blanch P, Ibernón M, Padró J, Delso J, Sobrepera JL, et al. Identificación de factores responsables de anticoagulación oral excesiva en pacientes ambulatorios con cardiopatía. Rev Esp Cardiol. 2003;56:65-72.
22. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-62.
23. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-8.
24. Pérez-Gómez F, Alegría E, Berjon J, Iriarte JA, Zumalde J, Salvador A, et al. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557-66.
25. Lorenzoni R, Lazzerini G, Cocci F, De Caterina, RL. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J. 2004;148:6.